Upload
others
View
8
Download
0
Embed Size (px)
Citation preview
www.wjpps.com Vol 6, Issue 9, 2017.
1084
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
FORMULATION AND EVALUATION OF ETORICOXIB METHYL
SALICYLATE MENTHOL MICROSPONGE GEL FOR TOPICAL
DRUG DELIVERY
*1
Vinayak K., 2Ashalatha,
3Shabaraya A. R. and
4A. Sravanthi
*1Asst, Professor, Srinivas College of Pharmacy, Valachil, Mangalore (Karnataka).
2Student, Srinivas College of Pharmacy, Valachil, Mangalore (Karnataka).
3Principal. HOD of Pharmaceutics Dept, Srinivas College of Pharmacy Valachil, Mangalore
(Karnataka).
4Asst. Professor, Srinivas College of Pharmacy, Valachil, Mangalore (Karnataka).
ABSTRACT
One of the most efficient approaches of novel drug delivery system for
topical application is Microsponges. These are polymeric delivery
systems composed of porous microspheres. They are tiny sponge-like
spherical particles with a large porous surface. Their high degree of
cross-linking results in particles that are insoluble, inert and of
sufficient strength to stand up to the high shear. Etoricoxib
Cyclooxigenase-2(cox-2) inhibitor a non steroidal anti-inflammatory
drug was formulated as microsponges using Ethyl cellulose and
Eudragit RS 100 polymers by solvent evaporation method and
evaluated for drug-polymer compatability by using FTIR, particle size,
production yield, loading efficiency, Further selected microsponges were formulated into gel
using carbopol 934(0.5% and 1%) and evaluated for various parameters like clarity, viscosity,
pH, spreadability, In-vitro diffusion, Skin irritation and stability studies were performed. And
it was found that all characteristic features shows significant results. The gel prepared by
these microsponges shows most efficient in uniform distribution and release rate of drug than
the any other form.
KEYWORDS: Etoricoxib, microsponges, gel, topical drug delivery, controlled release.
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
SJIF Impact Factor 6.647
Volume 6, Issue 9, 1084-1100 Research Article ISSN 2278 – 4357
*Corresponding Author
Vinayak K.
Asst, Professor, Srinivas
College of Pharmacy,
Valachil, Mangalore
(Karnataka).
Article Received on
23 June 2017,
Revised on 14 July 2017,
Accepted on 04 Aug. 2017
DOI: 10.20959/wjpps20179-9970
www.wjpps.com Vol 6, Issue 9, 2017.
1085
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
INTRODCTION
Microsponge drug delivery system
One of major approach to solve the Complications with topical formulation like unappealing,
greasiness, stickiness Un-controlled evaporation of active ingredient, unpleasant odour and
potential incompatibility of drugs with the vehicles is done by formulating into
microsponges. There highly cross-linked spherical polymeric nature provide sufficient
strength to with stand high shear results in particles that are insoluble, inert and of to
commonly used in manufacturing of creams, lotions, and powders. It have a capacity to
“load” a high degree of active materials in and on to the surface of the particle and also have
large capacity for entrapment of actives, up to three times its weight which differentiates
micro- sponge products from other types of dermatological delivery systems. the size of pore
diameter is smaller than bacteria, ranging from 0.007 to 0.2 µm prevents Bacterial
contamination of the materials entrapped in the microsponge, the release of drug can be
controlled through diffusion or other variety of triggers, including rubbing, moisture, pH,
friction, or ambient skin temperature. Microsponges are prepared by Liquid-liquid suspension
polymerization and Quassi-emulsion solvent diffusion.
MATERIAL AND METHODS
Organoleptic characteristics
The colour, odour and taste of the drug were characterized and recorded using descriptive
terminology.
Solubility study
The solubility of the Etoricoxib was determined in distilled water, phosphate buffer pH 6.8,
methanol, ethanol and dichloromethane by adding an excess amount of drug to 10 ml of
above solvents in conical flasks. The flasks were kept at 25±0.5°C in isothermal shaker for
24hrs to reach equilibrium. The equilibrated samples were removed from the shaker and
centrifuged at 4000 rpm for 15mins. The supernatant was taken and filtered through
whatmann filter paper. The concentration of Etoricoxib was determined in supernatant after
suitable dilution by using UV-visible spectrophotometer at 234 λmax.
Drug-excipient compatibility study
FTIR can be used to investigate and predict any physicochemical compatibility between
different excipients. IR spectra matching approach was used for detection of any possible
chemical compatibility between the drug and polymer. Scan was done in the range of 4000 to
www.wjpps.com Vol 6, Issue 9, 2017.
1086
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
400 cm-1
in a FTIR spectrophotometer (F.T.I.R, Shimadzu). The IR spectrum of the physical
mixture was compared with those of pure drug and polymer and peak matching was done to
detect any appearance or disappearance of peaks.
FORMULATION
Microsponge
The microsponges were prepared by quasi-emulsion solvent diffusion method[1,2]
The inner
phase was prepared by dissolving the Eudragit RS100/ Ethyl cellulose in 20 ml of
dichloromethane under sonication. This was followed by addition of Etoricoxib with stirring.
Outer phase was prepared by dissolving PVA in distilled water at 40˚C.The inner phase was
then added drop wise into outer phase with stirring at 1000 rpm. After 4hrs of stirring,
microsponges were formed due to the removal of solvent from the system by evaporation.
The microsponges were washed with water, filtered and dried at 40˚ C for 12hrs.
Table 1: Composition of Etoricoxib microsponges.
Ingredients F 1 F 2 F 3 F 4 F 5 F 6 F 7 F 8
Etoricoxib (gm) 1 1 1 1 1 1 1 1
Ethyl Cellulose (mg) 200 300 200 300 - - - -
Eudragit RS 100 (mg) - - - - 200 300 200 300
PVA(mg) 300 300 200 200 300 300 200 200
Dichloromethane(ml) 20 20 20 20 20 20 20 20
Water(ml) 200 200 200 200 200 200 200 200
EVALUATION OF MICROSPONGE
Particle size and shape[2]
The particle size was determined by using optical microscopy. It was used to determine the
shape and the outer structure of the particles.
Morphology and surface topography of the microsponges[2]
For morphology and surface topography, prepared microsponges were coated with gold-
palladium under an argon atmosphere at room temperature and then the surface morphology
of the microsponges was studied by scanning electron microscopy (SEM).
Drug content
The drug content was determined by dissolving 100 mg eq. weight of Etoricoxib
microsponge in 100 ml of PBS pH 6.8(stock solution “A”). From (stock solution “A”) 10ml
solution is diluted up to 100ml of PBS pH 6.8(stock solution “B”). From (stock solution “B”)
www.wjpps.com Vol 6, Issue 9, 2017.
1087
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
1ml solution is diluted up to 10ml with PBS PH 6.8. Then the absorbance is measured by Uv
spectrophotometer against blank at λ max 234 nm and the drug content was calculated.
Determination of loading efficiency and production yield[3]
The loading efficiency (%) of the microsponges was calculated according to the Following
equation.
The production yield of the microsponges was calculated by accurately weighing the initial
weight of the raw materials and the final weight of the microsponges obtained.
b) MICROSPONGE GEL[4,5]
Procedure
Required quantity of polymer was weighed and it was sprinkled slowly on surface of purified
water and kept for 24 hrs with continuous stirring by mechanical stirrer till uniformity was
obtained. With continuous stirring, triethanolamine was added to neutralize the gel and
maintain its pH. Appropriate quantity of microsponge of Etoricoxib was dissolved first in
ethanol along with weighed amount of menthol and methyl salicylate which was then added
to the gel. Finally Methyl Paraben was added to the gel with continuous stirring till get
dispersed in gel completely.
Table 2: Composition of Etoricoxib microsponge gel formulation.
Ingredients Polymer: Ethylcellulose Polymer:EudragitRS100
EMF1 EMF2 EMF3 EMF4
Etoricoxib Microsponge Eq.to1%
W/W
Eq.to1%
W/W
Eq.to1%
W/W
Eq.to1%
W/W
Carbopol 934 0.5% 1% 0.5% 1%
Menthol(mg) 50 50 50 50
Ethanol(ml) 2 2 2 2
Methyl paraben(gm) 0.09 0.09 0.09 0.09
Triethanolamine q.s q.s q.s q.s
Methyl salicylate 0.1% 0.1% 0.1% 0.1%
Purified water up to 10gm q.s q.s q.s q.s
www.wjpps.com Vol 6, Issue 9, 2017.
1088
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
Evaluation of Microsponge Gel formulation
Physical characteristics[6]
The gels were inspected visually for its colour, clarity, consistency, spreadability.
pH measurement[13]
The pH of microsponge formulation was determined by using digital pH meter.1gm of gel
was dissolved in 100ml of distil water and it was placed for 2hr. the measurement of pH of
each formulation was done in triplicate and average values were calculated.
Spreadability[7]
For the determination of spreadability, excess of sample was applied in between two glass
slides and was compressed to uniform thickness by placing 125g weight for 5 min. weight (1
g) was added to the pan. The time in which the upper glass slide moves over to the lower
plate was taken as measure of spread ability.
S = M.L / T
M- Weight tied to the upper slide
L - Length moved on the glass.
T - Time Taken
Clarity[8]
All developed gels were tested for homogeneity by visual inspection after the gels were set in
the container and also for presence of any aggregate.
1. Content uniformity[9]
Drug content of gel was determined by dissolving accurately weighed 1gm of gels in
Phosphate buffer pH 6.8. After suitable dilution absorbance was recorded by using UV-
visible spectrophotometer (Jasco) at 234 nm. Drug content was determined using slope of
standard curve.
2. Viscosity measurement[10]
Brookfield viscometer was used for viscosity determination. The formulation (10g) was taken
and it was allowed to calibrate for 5min before measuring the dial reading using spindle no
64 at 20rpm.
3. In-vitro drug diffusion study of the prepared gel[2]
The diffusion medium used was Phosphate buffer pH 6.8, carried out using Franz diffusion
www.wjpps.com Vol 6, Issue 9, 2017.
1089
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
cell. The diffusion cell was placed on the magnetic stirrer the outlet of the reservoir was
maintained at 37±0.5ºC. The receptor compartment was filled with Phosphate buffer pH 6.8,
pre hydrated cellophane paper was used as the membrane. The speed of the stirrer was kept
constant. 2ml of sample was pipetted out for every 1hr time interval.
4. Skin irritation study[11]
Selection of animal: Two healthy rabbits, weighing 2kg were selected for study. the
experimental protocol was subjected to the scrutiny of the institutional animal ethics
committee (Ref: SCP/IAEC/F150/P95/2016) date: 27/01/2016 and was cleared by same
before being the experiment.
0.5 gm of sample was evenly applied to a small area of (2 cm square) of the closely clipped
skin of each of the two rabbits. The site of application was secured with cotton gauze and it
was covered with a semi-occlusive dressing. One site served as test whiles the other as
control. At the termination of 4 hours of exposure period, the bandages/gauze was removed
and the treatment sites were cleaned with wet gauze to remove any residual test substance.
Skin reaction and sensitivity at the site of application was subjectively assessed and scored
once daily at 1, 24, 48, 72 hours, 7 and 14 days after patch removal. A ‐ No reaction, B ‐
Slight, patchy erythema, C ‐ Slight but confluent or moderate but patchy erythema, D ‐
Moderate erythema, E ‐ Severe erythema with or without edema.
Table 3: Classification systems for skin irritation study.
Reaction Score
Erythema 1
No erythema 0
Very slight erythema 2
Negligible irritation 0
Slight irritation 0.4 – 0.5
Moderate irritation 0.5 – 1.9
Severe irritation 1.9- 2
Redness 1
No redness 0
5. Stability Study[12]
The prepared microsponge gel formulations were subjected to stability studies as per ICH
Guidelines. The selected batch was packed in tightly closed containers wrapped in aluminium
foil and kept at 25±20c at (60±5%RH) for 60 days in a stability chamber and also at 2-8
0c
temperature in a refrigerator.
www.wjpps.com Vol 6, Issue 9, 2017.
1090
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
RESULTS AND DISSCSSION
Preformulation study of etoricoxib
Table 4: Organoleptic properties of Etoricoxib.
Properties Reported Observed
Appearance white to off-white powder white to off-white powder
Taste Tasteless Tasteless
Odour Odorless Odorless
Table 5: Solubility of Etoricoxib.
Solvents Reported Observed
Distilled water 0.01gm/ml 0.008gm/ml
Phosphate buffer pH 6.8 0.07gm/ml 0.055gm/ml
Ethanol 1.0gm/ml 0.91gm/ml
Methanol 1.2gm/ml 1.11gm/ml
Dichloromethane 1.10gm/ml 1.06gm/ml
Drug excipients compatibility studies: (Fourier Transform Infrared Spectroscopy)
Figure 1: F.T.I.R spectra of pure drug Etoricoxib.
Figure 2: FTIR spectra of Etoricoxib + ethyl cellulose
www.wjpps.com Vol 6, Issue 9, 2017.
1091
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
Figure 3: F.T.I.R spectra of pure drug Etoricoxib + Eudragit RS100.
Figure 4: F.T.I.R spectra of pure drug Etoricoxib+ Carbopol 934.
EVALUATION OF ETORICOXIB MICROSPONGES
Table 6: Evalation of particle size, production yield, drug content and loading efficiency
Formulation
code
Average particle
size (µm)
Production
yield (%)
Actual drug
content (%)
Loading
efficiency (%)
F1 77.34 83.33±0.23 75.7 75.5±0.35
F2 90.3 86.15±0.30 72.4 72.65±0.24
F3 113.48 75.83±0.41 77.2 77.55±0.31
F4 170.49 89.23±0.27 73.6 74.3±0.49
F5 80.15 84.16±0.29 77.8 77.5±0.35
F6 97.12 82.55±0.51 73.9 73.5±0.35
F7 128.08 90.83±0.41 79.01 79.5±0.35
F8 177.94 96.15±0.30 76.2 76.5±0.35
www.wjpps.com Vol 6, Issue 9, 2017.
1092
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
Surface topography and morphology of Etoricoxib microsponges
Figure 5: Scanning Electron Microscope image of microsponge surface of F3
microsponge formulation.
Figure 6: Scanning Electron Microscope image of F3 microsponge formulation.
EVALUATION OF ETORICOXIB MICROSPONGE GEL.
Table 7: Physical characteristics of etoricoxib microsponge gel.
Formulation
code Clarity pH
Spreadability
(gms.cm/sec)*
Drug
content
(%)
Viscosity
(cp)
EMF1 +++ 6.9±0.035 18.05±0.103 80.49% 23500
EMF2 ++ 6.8±0.035 28.13±0.0042 83.65% 24890
EMF3 +++ 6.3±0.035 19.78±0.1157 81.85% 24060
EMF4 ++ 6.4±0.035 27.45±0.0151 85.13% 26490
Clarity: + (turbid), ++ (clear), +++(very clear, glassy) * Average of 3 trials (average + S.D)
(n=3).
www.wjpps.com Vol 6, Issue 9, 2017.
1093
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
Table 8: In-vitro permeation data of Etoricoxib microsponge gel
Time
(Hrs)
% Cumulative drug release
EMF1 EMF2 EMF3 EMF4
1 16.631 16.908 17.364 17.856
2 27.774 24.757 27.734 30.320
3 34.572 32.264 35.360 38.013
4 39.917 39.555 41.538 45.192
5 43.255 44.692 44.407 50.033
6 46.448 50.016 47.507 54.386
7 48.108 54.936 49.340 57.579
12 54.305 67.096 56.557 69.227
Figure 7: Graph of %CDR v/s time of Etoricoxib microsponge gel formulations.
KINETIC STUDY OF MICROSPONGE GEL
Figure 8: Graph of Zero order release kinetics of Etoricoxib microsponge gel.
www.wjpps.com Vol 6, Issue 9, 2017.
1094
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
Formulations
Figure 9: First order release kinetics of Etoricoxibmicrosponge gel.
Figure 10: Korsmeyer-Peppas release kinetics of Etoricoxib microsponge gel.
Figure 11: Graph of Higuchi matrix release kinetics of Etoricoxib microsponge gel.
www.wjpps.com Vol 6, Issue 9, 2017.
1095
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
Table 9: Kinetics release study of Etoricoxib umicrosponge gel formulations.
Formulation
code
Zero
order
First
order
Higuchi
matrix
Peppas plot
R2 values n values
EMF1 0.752 0.837 0.958 0.754 0.254
EMF2 0.888 0.972 0.991 0.778 0.245
EMF3 0.765 0.855 0.963 0.754 0.257
EMF4 0.835 0.946 0.985 0.766 0.258
Figure 12: Skin irritation test data of the best formulation of microsponge gel.
Table 10: Observed results of skin irritation tests.
Time period
Microsponge topical gel
EMF2 EMF4
A B A B
Before application 0 0 0 0
1 hr 0 0 0 0
24 hrs 0 0 0 0
48 hrs 0 0 0 0
72 hrs 0 0 0 0
7 days 0 0 0 0
14 days 0 0 0 0
A: Control B: Test
www.wjpps.com Vol 6, Issue 9, 2017.
1096
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
Stability studies of the selected formulations (EMF2 and EMF4)
Table 11: Evaluation of physicochemical parameters of the formulation EMF2.
Physicochemical
Parameters
Time (Days)
0 30 60
pH A* 6.8 6.8 6.8
Drug Content (%) A* 83.8 82.5 82
Viscosity(cps)** A* 24890 24889 24887
Table 12: Evaluation of physicochemical parameters of the formulation EMF4.
Physicochemical parameters
Time (Days)
0 30 60
pH A* 6.4 6.4 6.4
Drug Content (%) A* 84.5 84.1 83.8
Viscosity(cps)** A* 26490 26488 26487
A*: 25±2°C and 60±5% RH, **: Viscosity measured at 100 rpm.
Table 13: In-vitro diffusion studies of formulation EMF2.
Time
(hrs)
%CDR
At 0 day
After 30 Day After 60 day
25±2°C and
60±5% RH
25±2°C and
60±5% RH
1 16.908 16.589 16.268
2 24.757 24.492 24.098
3 32.264 31.924 31.756
4 39.555 39.326 39.100
5 44.692 44.387 44.035
6 50.016 49.893 49.559
7 54.936 54.692 54.401
12 67.096 66.896 66.694
Figure 13: Graph of %CDR v/s Time of stability study of EMF2 formulation.
www.wjpps.com Vol 6, Issue 9, 2017.
1097
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
Table 14: In-vitro diffusion studies of formulation EMF4.
Time
(hrs)
%CDR
At 0 day
After 30 Day After 60 day
25±2°C and
60±5% RH
25±2°C and
60±5% RH
1 17.856 17.558 17.256
2 30.320 30.092 29.889
3 38.013 37.713 37.513
4 45.192 44.892 44.599
5 50.033 49.833 49.649
6 54.386 54.102 53.889
7 57.579 57.259 56.934
12 69.227 68.923 68.669
Figure 14: Graph of %CDR v/s Time of stability study of EMF4 formulation.
DISCUSSION
Etoricoxib microsponges were prepared by Quasi-emulsion solvent diffusion method using
Eudragit RS 100 and Ethyl cellulose as rate controlling polymers. It was then evaluated for
physicochemical properties like organoleptic properties, melting point, solubility, drug
polymer compatibility studies using FTIR and drug content. The best formulation for the
preparation of gel was selected on the basis of drug content of microsponge and it was
evaluated for parameters like pH, drug content, viscosity, In-vitro diffusion study and
primary skin irritation test. Stability studies were performed as per ICH guidelines (Q1A).
The melting point of Etoricoxib was found to be 136.5˚C, Etoricoxib is freely soluble in
methanol, ethanol, and dichloromethane and sparingly soluble in water. The study was
carried out to select suitable dissolution medium for in-vitro release studies, phosphate buffer
www.wjpps.com Vol 6, Issue 9, 2017.
1098
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
of pH 6.8 was selected for dissolution studies. By FTIR study it was found that there was no
interaction of Drug –polymer confirming the stability of drug in the formulations. Etoricoxib
microsponges were prepared by Solvent evaporation method using Eudragit RS100 and
ethylcellulose as rate controlling polymers. Microsponge formulations were prepared and
evaluated for production yield, loading efficiency, drug content and morphology studies.
Based on the drug content data F-3 and F-7 formulations were selected and incorporated into
carbopol 934gel and evaluated for physicochemical properties, drug content, primary skin
irritation test and diffusion studies. production yield and loading efficiency were calculated
for all the microsponge formulations, upto 96.15±0.30% of production yield and 79.5±0.35%
of loading efficiency was found with microsponges of both the polymers. The drug content of
formulation F3 using ethyl cellulose shows 72-77%. The morphology of the selected
microsponge formulation were investigated by SEM. it was observed by SEM analysis that
the microsponges were finely spherical, uniform in shape, no intact drug crystals are seen
visually and inner structure was consist of porous in nature with void spaces.
Physicochemical evaluation of Etoricoxib microsponge gels like clarity, pH determination,
Viscosity studies, Spreadability, Drug content uniformity, In-vitro diffusion study, Skin
irritation study, was performed it was found that clear with moderate viscocity and
28.13±0.0042gm.cm/sec of spreadability was obsereved, in the drug content study 85.13%
was observed. The highest cumulative percentage amount of the drug released from the
microsponge gel at the end of 12hrs was found to be 69.227%. During skin irritation test till
14th
day no such irritation was observed and there were no significant changes observed after
3 months of stability testing.
CONCLUSION
The present study has been satisfactory attempt has been made to formulation and evaluation
of etoricoxib methyl salicylate menthol microsponge gel for topical drug delivery. From the
reproducible results of executed experiments: it can be concluded that Preformulation studies
on Etoricoxib comply with the reported literature limits. The FTIR spectra revealed that there
was no interaction between drug and polymer. From, the present study it can be concluded
that microsponge can be prepared by Quasi-emulsion solvent diffusion method using
different concentration of Ethyl cellulose and Eudragit RS100 as the rate controlling
polymers. All the microsponge formulations were subjected to particle size, production yield,
loading efficiency, drug content, SEM. F3 and F7 microsponge selected as best formulation
and conveniently incorporated into carbopol 934 (0.5%) and (1%) gel. All the formulations of
www.wjpps.com Vol 6, Issue 9, 2017.
1099
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
gels were evaluated for various parameters like clarity, viscosity, pH, spreadability, drug
content, in-vitro diffusion studies, depending upon the in-vitro release value the formulation
was subjected to kinetic analysis and the results were found to be reproducible. The skin
irritation test was performed on rabbits according to Draize patch test. The results suggest
that neither there is edema nor symptoms of adverse effects hence’0’ score was given after
each observation indicating Etoricoxib microsponge gel can be conveniently incorporated
into gels without any irritation. Stability studies as per ICH guidelines (Q1A) of formulation
EMF2 and EMF4 were carried out for short duration of time (3 month). There was no
significant change found in the evaluation of microsponge gel which indicates that the
formulation EMF2 and EMF4 is fairly stable at storage conditions.
REFERENCES
1. Orlu M, Cevher E, Araman A. Design and evaluation of colon specific drug delivery
system containing flurbiprofen microsponges. Int J Pharm, 2006; 318(1-2): 103-17.
2. Santanu K, Sabyasachi M, Ashok KG, Shubham B. Microsponge: A novel strategy for
drug delivery system. J Adv Pharm Tech Res, 2010; 1(3): 283-90.
3. Vyas SP, Khar RK. Targeted and controlled drug delivery- Novel carrier system, New
Delhi, CBS publication, 2002; ed.1st: 453.
4. Mehta M, Panchal A, Shah VH, Upadhyay U. Formulation and in-vitro Evaluation of
controlled release microsponge gel for topical delivery of Clotrimoazole. Int J Adv
pharm, 2012; 2(2): 93-101.
5. Roohi K, Anupam S, Swati S, Dilip P. Formulation and Evaluation of Solid Lipid
Nanoparticle (SLN) Based Topical Gel of Etoricoxib. JA Pharm Sci, 2016; 6(10):
124-131.
6. D’souza JI, Harinath NM. Topical anti-inflammatory gels of fluocinolone acetonide
entrapped in Eudragit based microsponge delivery system. Res J Pharm Tech, 2008; 1(4):
502-06.
7. A.P.Pharma Inc. Microsponge Technology, Topical Technology 2001; Available at:
http://www.appharma.com/PDFs/topicalsht.pdf.
8. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the
treatment of melisma and post inflammatory hyperpigmentation. Acta Pharm, 2004;
74(6): 362-68.
www.wjpps.com Vol 6, Issue 9, 2017.
1100
Vinayak et al. World Journal of Pharmacy and Pharmaceutical Sciences
9. Jayaraj K, Jayachandran E, Sreenivas GM. Formulation and evaluation of in-situ gels
containing ciclopriox olamine for oral thrush. J Innovative trends Pharm Sci, 2010; 1(5):
204-10.
10. Ravi PP, Raghavendra NG, Chowdary S. Formulation evaluation and anti-inflammatory
activity of topical etoricoxib gel. Asian J pharm clinical res, 2010; 3(2): 126-29.
11. Emanuele AD, Dinarvand R. Preparation, characterization and drug release from thermo
responsive microspheres. Int J Pharm, 1995; 2(1): 237-42.
12. ICH guidelines Q1A (R2). Stability testing of new drug substaces and products, 6th
feb
(2003).
13. Dinesh Chandra, Sarvesh Kumar Singh, Jayant Kumar Maurya, Santosh Singh, Vikash
Mishra and Ravi Rai. Formulation and Evaluation of Etoricoxib Topical Gel using
Different Gelling Agent and Different Penetration Enhancer. Am. J. Pharm Tech Res,
2013; 3(6): 456-461.